Neko Health and Neuralink Partner to Screen Trial Participants

The tie-up matters less as a product story than as a signal about how neurotech trials may source and qualify participants: pairing an implant developer with an independent screening provider could tighten candidate selection and, by extension, the safety narrative around invasive brain-computer interfaces. It also nudges Neuralink's recruitment toward a commercial health-screening partner rather than purely clinical channels, a shift worth watching across the sector. Whether such screening partnerships become standard practice for implantable-device trials, or remain a one-off arrangement, is the open question.